Cargando…
Integrating the Synergy of the Gut Microbiome into Regenerative Medicine: Relevance to Neurological Disorders
A new paradigm of cell therapy-based approaches as a solution to several diseases caused by damage or loss of cells/tissues leading to organ failure heralded the birth of a new branch in medicine called regenerative medicine (RM), which was further fueled by in vitro cell expansion and tissue engine...
Autores principales: | Preethy, Senthilkumar, Ranganathan, Natarajan, Raghavan, Kadalraja, Dedeepiya, Vidyasagar Devaprasad, Ikewaki, Nobunao, Abraham, Samuel J.K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277691/ https://www.ncbi.nlm.nih.gov/pubmed/35466942 http://dx.doi.org/10.3233/JAD-220313 |
Ejemplares similares
-
Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomised, parallel-group pilot clinical study
por: Raghavan, Kadalraja, et al.
Publicado: (2022) -
Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential applications in human health and disease
por: Preethy, Senthilkumar, et al.
Publicado: (2022) -
Benefits of Gut Microbiota Reconstitution by Beta 1,3–1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases
por: Raghavan, Kadalraja, et al.
Publicado: (2023) -
Corrigendum to “Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study” [IBRO Neurosci. Rep. 15 (2023), pp. 90–99]
por: Raghavan, Kadalraja, et al.
Publicado: (2023) -
Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study
por: Raghavan, Kadalraja, et al.
Publicado: (2023)